$599

New Lilly Ph1 Trial; Likely GGG Tri-agonist

Lilly has initiated a new Ph1 trial evaluating an unknown compound (LY3437943) vs. Trulicity in T2DM patients. Below, FENIX has conducted an analysis to help identify the compound and potential MOA.

This content is for Read Less members only.
Register
Already a member? Log in here